Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy

被引:49
作者
Stock, Richard G. [1 ]
Cesaretti, Jamie A. [1 ]
Hall, Simon J. [2 ]
Stone, Nelson N. [2 ]
机构
[1] Mt Sinai Sch Med, Dept Radiat Oncol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Urol, New York, NY 10029 USA
关键词
prostate cancer; Gleason score 8-10; brachytherapy; external beam radiotherapy; hormonal therapy; RADICAL PROSTATECTOMY; ANDROGEN DEPRIVATION; RADIATION-THERAPY; GLEASON SCORE; FREE SURVIVAL; BIOPSY; ANTIGEN; ADENOCARCINOMA; IRRADIATION; SUPPRESSION;
D O I
10.1111/j.1464-410X.2009.08661.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess the outcomes for patients with Gleason score 8-10 prostate cancer treated with brachytherapy, external beam radiotherapy (EBRT) and hormonal therapy (HT). PATIENTS AND METHODS In all, 181 patients with Gleason scores 8-10 prostate cancer were treated from 1994 to 2006 with a 103Pd implant (prescription dose 100 Gy), 45 Gy of EBRT and 9 months of HT. The median (range) follow-up was 65 (24-150) months; freedom from biochemical failure (FBF) rates were calculated using the Phoenix definition. RESULTS The 8-year actuarial FBF, freedom from distant metastases, prostate-cancer specific survival and overall survival were 73%, 80%, 87% and 79%, respectively. The pretreatment prostate-specific antigen (PSA) level significantly affected FBF, with 8-year rates of 72%, 82% and 58% for patients with PSA level of < 10, > 10-20 and > 20 ng/mL, respectively (P = 0.006). The PSA level had no significant effect on rates of distant metastases. The Gleason score had the most significant affect on FBF in a multivariate analysis, and was the only factor to significantly affect rates of distant metastases; the 8-year FBF rates were 84%, 55% and 30% for scores of 8, 9 and 10, respectively (P = 0.003). The corresponding freedom from distant metastases and prostate-cancer specific survival rates were 86%, 76%, 30% (P < 0.001) and 92%, 80%, 62.5% (P = 0.003), respectively. CONCLUSIONS The 8-year outcomes after this regimen showed favourable biochemical and distant control, as well disease-specific survival rates for patients with Gleason scores of 8-10. This treatment approach should be considered as a viable option for this subset of patients with high-risk disease.
引用
收藏
页码:1631 / 1636
页数:6
相关论文
共 50 条
[41]   Role of Isotope Selection in Long-term Outcomes in Patients With Intermediate-risk Prostate Cancer Treated With a Combination of External Beam Radiotherapy and Low-dose-rate Interstitial Brachytherapy [J].
Wernicke, A. Gabriella ;
Shamis, Michael ;
Yan, Weisi ;
Trichter, Samuel ;
Sabbas, Albert M. ;
Goltser, Yevgenia ;
Christos, Paul J. ;
Brennan, Jennifer S. ;
Parashar, Bhupesh ;
Nori, Dattatreyudu .
UROLOGY, 2012, 79 (05) :1098-1104
[42]   Efficacy of brachytherapy combined with endocrine therapy and external beam radiotherapy in the treatment of intermediate and high-risk localized prostate cancer [J].
Zhang, Wei ;
Zhou, Huiyan ;
Qin, Mengxian ;
Zhang, Xuehai ;
Zhang, Jiarui ;
Chai, Shengwu ;
Song, Junyan .
JOURNAL OF BUON, 2020, 25 (05) :2405-2411
[43]   Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer [J].
Kamitani, Nobuhiko ;
Watanabe, Kenta ;
Ikeda, Naoki ;
Kawata, Yujiro ;
Tokiya, Ryoji ;
Hayashi, Takafumi ;
Miyaji, Yoshiyuki ;
Tamada, Tsutomu ;
Katsui, Kuniaki .
JAPANESE JOURNAL OF RADIOLOGY, 2024, 42 (11) :1322-1329
[44]   Combination external beam radiation and brachytherapy boost for prostate cancer [J].
Chapet, O. ;
Bossi, A. ;
Horn, S. ;
Crehange, G. .
CANCER RADIOTHERAPIE, 2017, 21 (6-7) :473-477
[45]   High biologically effective dose radiation therapy using brachytherapy in combination with external beam radiotherapy for high-risk prostate cancer [J].
Okamoto, Keisei ;
Wada, Akinori ;
Kohno, Naoaki .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2017, 9 (01) :1-6
[46]   Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy [J].
Stone, Nelson N. ;
Stock, Richard G. .
BJU INTERNATIONAL, 2019, 123 (02) :277-283
[47]   An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy [J].
Gabriele, Domenico ;
Guarneri, Alessia ;
Bartoncini, Sara ;
Munoz, Fernando ;
Tamponi, Matteo ;
Russo, Filippo ;
Stamatakos, Georgios ;
Guiot, Caterina ;
Regge, Daniele ;
Ricardi, Umberto .
RADIATION ONCOLOGY, 2021, 16 (01)
[48]   Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy [J].
Taira, Al V. ;
Merrick, Gregory S. ;
Galbreath, Robert W. ;
Butler, Wayne M. ;
Lief, Jonathan H. ;
Adamovich, Edward ;
Wallner, Kent E. .
BRACHYTHERAPY, 2013, 12 (05) :408-414
[49]   Long-term outcome of high-risk prostate cancer treated with brachytherapy combined with external-beam radiation therapy and androgen deprivation therapy [J].
Chen, Jian ;
Yan, Wei-gang ;
Li, Han-zhong ;
Ji, Zhi-gang ;
Zhou, Yi ;
Zhou, Zhi-en ;
Mai, Zhi-peng .
TUMORI JOURNAL, 2014, 100 (05) :524-528
[50]   Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External-beam Radiotherapy [J].
Tanji, Nozomu ;
Kikugawa, Tadahiko ;
Ochi, Takashi ;
Taguchi, Senzo ;
Sato, Hideki ;
Sato, Takeshi ;
Sugahara, Takeshi ;
Hamada, Hitoshi ;
Asai, Seiji ;
Matsumoto, Atsushi .
ANTICANCER RESEARCH, 2015, 35 (06) :3379-3391